CA
NZ
UK
AU
IND
US
Pfizer Inc. (NYSE: PFE) received U.S. regulatory clearance for a new bladder cancer treatment, driving its stock higher as investors anticipate additional revenue opportunities. The FDA approved PADCEV in combination with Keytruda for adults with muscle-invasive bladder cancer (MIBC), broadening the therapy’s application beyond …
Q32 Bio has obtained fresh capital through a public offering where the shares were priced at $18.25, a modest discount to the prior closing level. The underwriting syndicate retained a 30‑day option to buy up to 1,643,835 further shares, providing flexibility for additional funding …
IRIDEX shareholders approved all director nominees and ratified the auditor at the company’s annual meeting, but the vote revealed a stealth proxy campaign targeting two independent directors. The company, which specializes in laser-based medical systems, reported financial progress. However, the meeting’s adjournment and subsequent …
With shares down 97.2% year-to-date, the microcap biotech is advancing its clinical program despite significant market skepticism.
LataMed AI Corp. has completed a forward stock split, a move designed to enhance share liquidity as the company accelerates its telehealth and artificial intelligence initiatives across Latin America. The split became effective at the opening of trading in mid‑July 2026, following publication on …
Mobia Medical has enhanced its governance by appointing a veteran medical technology leader to its board. The company, which specializes in minimally invasive surgical devices, welcomed Reza Zadno as an independent director. This addition increases the board’s size and brings expertise in surgical robotics …
Intuitive Surgical delivered a stronger-than-expected quarter, reporting earnings per share of $2.50 that surpassed the $2.14 consensus estimate. The beat comes as BMO Capital initiated coverage with an Outperform rating and a $518 price target, sending shares up 2.9% in recent trading.
Ensysce Biosciences (NASDAQ: ENSC) has announced another change in its leadership team, continuing a pattern of executive transitions at the micro-cap biotechnology firm. The departure, disclosed through a recent regulatory filing, reflects ongoing shifts in the company's management structure as it navigates the challenges …
Erasca Inc. (NASDAQ: ERAS) witnessed its share price jump 8.9% to $19.50 after a Phase 1 investigation of its ERAS‑0015 candidate reported a 57% shrinkage of pancreatic tumors. The company posted a loss per share that fell short of analyst expectations for the most …
The clinical research sector is undergoing a significant transformation as the Association of Clinical Research Professionals (ACRP) updates its certification programs to align with the ICH E6(R3) global standards. This change will affect thousands of professionals and reshape how clinical trials are planned, monitored, …
Please wait processing your request...